To Evaluate the Long-term Safety and Efficacy of HSK16149 in Chinese Patients With Peripheral Neuralgia

NCT05890053 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

301

Enrollment

INDUSTRY

Sponsor class

Conditions

Peripheral Neuropathic Pain

Interventions

DRUG: HSK16149 40mg BID

Sponsor

Haisco Pharmaceutical Group Co., Ltd.